Janssen adds Astellas JAK inhibitor to its immunology portfolio PMLiVE Astellas will continue its in-house development of the drug for the prevention of organ transplant rejection, where the clinical programme has reached phase II. Meanwhile, Pfizer's tofacitinib is on-track to become the first JAK inhibitor to reach the ... |
